MedTrace Logo

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

NCT05891379 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-09-19

No results posted yet for this study

Summary

This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.

Conditions

Interventions

DRUG

Inebilizumab

Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.

DRUG

oral immunosuppressant

Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Junwei Hao, MD · Xuanwu Hospital, Beijing

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891379 on ClinicalTrials.gov